Who are Evoxac's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Northera, Vesicare, Detrol, Provocholine, Atrovent, HEXOCYCLIUM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cevimeline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Evoxac — Competitive Intelligence Brief

Evoxac (CEVIMELINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinergic Receptor Agonist. Area: Neuroscience.

marketed Cholinergic Receptor Agonist Muscarinic acetylcholine receptor M1 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Evoxac (CEVIMELINE) — Cosette.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Evoxac TARGET	CEVIMELINE	Cosette	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	2000-01-01
Northera	DROXIDOPA	Lundbeck Na Ltd	marketed	Catecholamine	Muscarinic acetylcholine receptor M1	2014-01-01
Vesicare	SOLIFENACIN	Astellas Pharma	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	2004-01-01
Detrol	TOLTERODINE	Upjohn	marketed	Cholinergic Muscarinic Antagonist	Muscarinic acetylcholine receptor M1	1998-01-01
Provocholine	METHACHOLINE	Methapharm	marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M1	1986-01-01
Atrovent	IPRATROPIUM		marketed	Anticholinergic	Muscarinic acetylcholine receptor M1	1986-01-01
HEXOCYCLIUM	HEXOCYCLIUM	AbbVie	marketed	hexocyclium	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3	1982-01-01

Recent regulatory actions (last 90 days)

2026-02-23 — Atrovent · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinergic Receptor Agonist class)

· 2 drugs in this class
Cosette · 1 drug in this class
Methapharm · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Evoxac — Competitive Intelligence Brief. https://druglandscape.com/ci/cevimeline. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab